34% of African trials have explicit affiliations with Western universities.
Western Affiliation
34%
Key Institutions
Oxford, Cambridge
Local Leadership
Often secondary
Impact
Agenda-setting
Key Finding
Western academic institutions frequently occupied the principal investigator and sponsor positions, shaping the research questions, methodologies, and publication strategies for trials conducted on African soil.
Regional Comparison
Hiv — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Placebo: AF 3,324 vs US 33,931 (10.2x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Elite Western universities maintain a massive clinical footprint in Africa, often exceeding the leadership presence of local institutions. Oxford, Cambridge, Johns Hopkins, and Harvard frequently set the research agenda for African studies. While these partnerships bring resources and expertise, they also entrench a structural hierarchy where scientific priorities are defined in the Global North.
The Evidence 152 words · target 156
In institutional analysis, does the presence of elite Western academic institutions in African clinical trials indicate intellectual partnership or structural hegemony? This audit estimated that thirty-four percent of 23,873 African interventional trials on ClinicalTrials.gov had explicit affiliations with top-tier Western institutions including Oxford, Cambridge, Johns Hopkins, and Harvard through March 2026. Investigators reported the academic penetration rate as the primary estimand for institutional influence. Western academic institutions frequently occupied the principal investigator and sponsor positions, shaping the research questions, methodologies, and publication strategies for trials conducted on African soil. The 1,793 HIV trials showed the strongest Western academic footprint through PEPFAR-affiliated networks at Uganda and Kenya institutions. Local African institutional leadership was most prominent in Egypt where domestic universities led the majority of the 11,752 registered trials. These findings reveal a structural hierarchy where scientific priorities are frequently defined in the Global North. Interpretation is limited by name-matching heuristics for institutional identification.
Sentence Structure
Question
In institutional analysis, does the presence of elite Western academic institutions in African clinical trials indicate intellectual partnership or structural hegemony?
Dataset
This audit estimated that thirty-four percent of 23,873 African interventional trials on ClinicalTrials.gov had explicit affiliations with top-tier Western institutions including Oxford, Cambridge, Johns Hopkins, and Harvard through March 2026.
Method
Investigators reported the academic penetration rate as the primary estimand for institutional influence.
Primary Result
Western academic institutions frequently occupied the principal investigator and sponsor positions, shaping the research questions, methodologies, and publication strategies for trials conducted on African soil.
Robustness
The 1,793 HIV trials showed the strongest Western academic footprint through PEPFAR-affiliated networks at Uganda and Kenya institutions.
Interpretation
Local African institutional leadership was most prominent in Egypt where domestic universities led the majority of the 11,752 registered trials.
Boundary
These findings reveal a structural hierarchy where scientific priorities are frequently defined in the Global North.